SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 137 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,092 | -59.5% | 212,967 | -41.7% | 0.01% | -53.8% |
| Q2 2023 | $7,643 | -25.3% | 365,172 | -24.7% | 0.03% | -29.7% |
| Q1 2023 | $10,236 | +19.7% | 484,666 | +44.2% | 0.04% | +19.4% |
| Q4 2022 | $8,552 | -99.9% | 335,996 | +0.3% | 0.03% | +6.9% |
| Q3 2022 | $8,049,000 | +32.8% | 334,963 | +6.4% | 0.03% | +38.1% |
| Q2 2022 | $6,059,000 | +18.9% | 314,914 | +7.4% | 0.02% | +50.0% |
| Q1 2022 | $5,098,000 | -19.1% | 293,349 | +1.8% | 0.01% | 0.0% |
| Q4 2021 | $6,305,000 | +13.4% | 288,052 | -1.0% | 0.01% | +7.7% |
| Q3 2021 | $5,558,000 | +9.9% | 290,844 | -1.3% | 0.01% | +8.3% |
| Q2 2021 | $5,058,000 | – | 294,609 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |